Navigation Links
Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
Date:7/17/2012

EAST BRUNSWICK, N.J., July 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's second quarter 2012 financial results will be released prior to the market open on Wednesday, August 8, 2012.  Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on August 8, 2012 to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 99954484.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.
A telephone replay will be available for fourteen days by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 99954484.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.  

SVNT-IContact: Mary Coleman 

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com 

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
2. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
5. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
6. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
7. 81,200 Square Foot Lease Extension In San Diego Through 2018 Signed By Vertex Pharmaceuticals And BioMed Realty
8. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
9. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
10. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
11. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
Breaking Medicine Technology:
(Date:8/19/2017)... (PRWEB) , ... August 18, 2017 , ... ... partnership aimed at creating a transparent, verifiable database to help the cannabis industry ... ledger technology, Paragon hopes to deliver a faster technology with lower fees. Paragon ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United ... are two sides. There are not two sides to hatred, bigotry, discrimination, and a ... prejudice, and the NPEIV stands against all forms of such hatred and discrimination in ...
(Date:8/18/2017)... ... ... More than 20,000 pairs of shoes made their way across the Atlantic ... that conjoined the passions of an NBA star, a Liberty University student, and an ... will save lives from the rampant infections transmitted through the soil. , AMERICAN SOLES ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance of proactive ... with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
Breaking Medicine News(10 mins):